Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GALENT-BT: Gemcitabine, nab-Paclitaxel, Lenvatinib, and Tislelizumab for Advanced Biliary Tract Malignancies
NCT06963060Phase 2Enrolling by invitation
- Start
- Jun 2024
- Primary completion
- Jun 2027
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab, lenvatinib, paclitaxel, gemcitabine in biliary tract cancer (BTC). Started Jun 2024; status: enrolling by invitation.
02
Drugs
tislelizumablenvatinibpaclitaxelgemcitabine
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT06963060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06963060.